Trials that use: Intention-to-treat analysis
New to this method? Read the tutorial →
7,779 results
- CALMextIndependent statistical analysis of CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext): primary endpoint results, effect estimate with confidence interval, sample-size…
- Caminamos: A Smartphone App to Connect With Walking Partners: Complete Statistical AnalysisIndependent statistical analysis of Caminamos: A Smartphone App to Connect With Walking Partners: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03059901).
- CAMMPSIndependent statistical analysis of Comprehensive vs. Assisted Management of Mood and Pain Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01757301).
- Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CAMPBELIndependent statistical analysis of CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CAMTAFIndependent statistical analysis of Catheter Ablation Versus Medical Treatment of AF in Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01411371).
- Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?: Complete Statistical AnalysisIndependent statistical analysis of Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?: Complete Statistical AnalysisIndependent statistical analysis of Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Can Massage During One Year Improve Health in Health-care Providers Working in Hospital: Complete Statistical AnalysisIndependent statistical analysis of Can Massage During One Year Improve Health in Health-care Providers Working in Hospital: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CAN QuitIndependent statistical analysis of Connecting Alaska Native People to Quit Smoking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03645941).
- Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?: Complete Statistical AnalysisIndependent statistical analysis of Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Can Virtual Reality Reduce Pain and Anxiety During Blood Draw: Complete Statistical AnalysisIndependent statistical analysis of Can Virtual Reality Reduce Pain and Anxiety During Blood Draw: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04449341).
- CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…
- Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months): Complete Statistical AnalysisIndependent statistical analysis of Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CANDLEIndependent statistical analysis of Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cangrelor Ticagrelor Transition Study: Complete Statistical AnalysisIndependent statistical analysis of Cangrelor Ticagrelor Transition Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01766466).
- Cannabidiol and Management of Endometriosis Pain: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol and Management of Endometriosis Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04527003).
- Cannabidiol in Youth Alcohol Use Disorder: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol in Youth Alcohol Use Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05317546).
- Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00588731).
- Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control: Complete Statistical AnalysisIndependent statistical analysis of Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05477875).
- Cannabinoids for Pain Control During Medical Abortion: Complete Statistical AnalysisIndependent statistical analysis of Cannabinoids for Pain Control During Medical Abortion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03604341).
- Cannabis for Spasticity in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Cannabis for Spasticity in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00682929).
- CANOPY-2Independent statistical analysis of Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy:…
- Canopy-AComplete statistical analysis of the phase 3 Canopy-A trial of canakinumab versus placebo as adjuvant therapy in completely resected non-small cell lung cancer, including disease-free survival, subgroup analyses, statistical methodology, safety, and…
- CANTATAIndependent statistical analysis of CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CANTOSAn independent statistical analysis of the phase 3 CANTOS trial (NCT01327846), comparing three canakinumab doses with placebo for first adjudicated major adverse cardiovascular events in 10066 participants with atherosclerosis, with hazard ratios,…
- Cap-assisted Water Immersion Versus Water Immersion Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Cap-assisted Water Immersion Versus Water Immersion Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01547247).
- CAP-CholIndependent statistical analysis of Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients: primary endpoint results,…
- Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates: Complete Statistical AnalysisIndependent statistical analysis of Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CAP’ONCOIndependent statistical analysis of CAP'Onco : Psychological and Social Consultation of Professional Accompaniment in Oncology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CAPACITYIndependent statistical analysis of Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04327843).
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL: Complete Statistical AnalysisIndependent statistical analysis of Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL: primary endpoint results, effect…
- CapAppIndependent statistical analysis of Capillary Refill Time Measurement Utilizing Mobile Application in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05472116).
- CAPEIndependent statistical analysis of Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05512962).
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00565370).
- Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00347438).
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…
- Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPICAIndependent statistical analysis of Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02202577).
- CAPITALCHILLIndependent statistical analysis of Mild Versus Moderate Therapeutic Hypothermia in Out-of-hospital Cardiac Arrest Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02011568).
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPPSIndependent statistical analysis of Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00135707).
- CAPSYSIndependent statistical analysis of Computer-Aided Prevention System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02444715).
- CAPYBARAIndependent statistical analysis of A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CARAVAGGIOIndependent statistical analysis of Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…